open access

Vol 89, No 2 (2018)
Review paper
Published online: 2018-02-28
Get Citation

The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update and literature review

Przemyslaw Kosinski1, Urszula Sarzynska-Nowacka1, Magdalena Fiolna2, Miroslaw Wielgos1
DOI: 10.5603/GP.a2018.0018
·
Pubmed: 29512816
·
Ginekol Pol 2018;89(2):107-111.
Affiliations
  1. 21st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland, Poland
  2. Fetal Medicine Unit, Medway Maritime Hospital, Gillingham, Kent, United Kingdom

open access

Vol 89, No 2 (2018)
REVIEW PAPERS Obstetrics
Published online: 2018-02-28

Abstract

It is now well established that acetylsalicylic acid — one of the most widely prescribed drugs today — has brought a new era in maternal-fetal medicine. The History of medicine mentions several antecedents. Extracts made from willow contained in clay tablets are reported in both ancient Sumer and Egypt. In 400 BC, Hippocrates referred to the use of salicylic tea to reduce fevers. In the 1950s, acetylsalicylic acid entered the Guinness Book of Records as the highest selling painkiller. There is little doubt that acetylsalicylic acid — one of the first drugs to enter common usage — remains one of the most researched drugs in the world.

Abstract

It is now well established that acetylsalicylic acid — one of the most widely prescribed drugs today — has brought a new era in maternal-fetal medicine. The History of medicine mentions several antecedents. Extracts made from willow contained in clay tablets are reported in both ancient Sumer and Egypt. In 400 BC, Hippocrates referred to the use of salicylic tea to reduce fevers. In the 1950s, acetylsalicylic acid entered the Guinness Book of Records as the highest selling painkiller. There is little doubt that acetylsalicylic acid — one of the first drugs to enter common usage — remains one of the most researched drugs in the world.

Get Citation
Supp./Additional Files (1)
Proofreading certificate
Download
171KB
About this article
Title

The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update and literature review

Journal

Ginekologia Polska

Issue

Vol 89, No 2 (2018)

Article type

Review paper

Pages

107-111

Published online

2018-02-28

DOI

10.5603/GP.a2018.0018

Pubmed

29512816

Bibliographic record

Ginekol Pol 2018;89(2):107-111.

Authors

Przemyslaw Kosinski
Urszula Sarzynska-Nowacka
Magdalena Fiolna
Miroslaw Wielgos

References (26)
  1. Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989; 321(6): 357–362.
  2. Kosiński P, Samaha RB, Bomba-Opoń DA, et al. Reference values for placental growth factor (PlGF) concentration and uterine artery doppler pulsatility index (PI) at 11-13(+6) weeks of gestation in the Polish population. Ginekol Pol. 2014; 85(7): 488–493.
  3. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010; 116(2 Pt 1): 402–414.
  4. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost. 2009; 7 Suppl 1: 258–261.
  5. Beaufils M, Uzan S, Donsimoni R, et al. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985; 1(8433): 840–842.
  6. Dekker GA, Sibai BM. Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. Am J Obstet Gynecol. 1993; 168(1 Pt 1): 214–227.
  7. Cadavid AP. Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications. Front Immunol. 2017; 8: 261.
  8. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets. 2006; 5(2): 91–106.
  9. Macdonald LJ, Boddy SC, Denison FC, et al. A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometrium. Reproduction. 2011; 142(2): 345–352.
  10. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008; 51(4): 970–975.
  11. Henderson JT, Whitlock EP, O'Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160(10): 695–703.
  12. Jackson JR, Gregg AR. Updates on the Recognition, Prevention and Management of Hypertension in Pregnancy. Obstet Gynecol Clin North Am. 2017; 44(2): 219–230.
  13. Al-Jabi SW. Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis. Basic Clin Pharmacol Toxicol. 2017; 121(6): 512–519.
  14. Navaratnam K, Alfirevic A, Alfirevic Z. Low dose aspirin and pregnancy: how important is aspirin resistance? BJOG. 2016; 123(9): 1481–1487.
  15. Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 216(2): 110–120.e6.
  16. Hermida RC, Ayala DE, Mojón A, et al. Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. Am J Hypertens. 2009; 22(8): 896–903.
  17. Hermida RC, Ayala DE, Iglesias M. Administration time-dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003; 41(3 Pt 2): 651–656.
  18. Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013; 30(1-2): 260–279.
  19. Ayala DE, Hermida RC. Sex differences in the administration-time-dependent effects of low-dose aspirin on ambulatory blood pressure in hypertensive subjects. Chronobiol Int. 2010; 27(2): 345–362.
  20. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006; 195(1): 40–49.
  21. Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013; 41(5): 491–499.
  22. Roberge S, Odibo AO, Bujold E. Aspirin for the Prevention of Preeclampsia and Intrauterine Growth Restriction. Clin Lab Med. 2016; 36(2): 319–329.
  23. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998; 338(11): 701–705.
  24. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017; 377(7): 613–622.
  25. O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016; 214(1): 103.e1–103.e12.
  26. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012; 31(3): 141–146.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl